In re Phenylpropanolamine (PPA) Products Liability Litigation Lawsuit

In re Phenylpropanolamine (PPA) Products Liability Litigation

• Product: Phenylpropanolamine (PPA), a sympathomimetic amine in decongestants and weight-loss products

• Manufacturer: a generic ingredient marketed under many brand names by multiple companies

• Court: United States District Court for the Western District of Washington

• Judge: Barbara J. Rothstein

• Docket: MDL No. 1407 (2:01-md-01407-BJR)

The product

Phenylpropanolamine (PPA), also known by the synonym norephedrine, is a sympathomimetic amine. For decades it was a common ingredient in prescription and over-the-counter products: as a nasal decongestant in cough-and-cold preparations and as an appetite suppressant in weight-loss formulations. The molecule was synthesized in the early twentieth century and entered medical use by the 1930s. By the 1990s it was sold under a long list of brand names, both as stand-alone products and in combination remedies, which meant that there was no single PPA manufacturer — many companies produced and distributed products containing the ingredient.

Pharmacologically, PPA is an indirectly acting sympathomimetic: it prompts the release of norepinephrine, which in turn stimulates adrenergic receptors. The expected side-effect profile therefore included elevated heart rate and blood pressure. The compound is chemically related to ephedrine and amphetamine, a family connection that later subjected it to methamphetamine-precursor controls in the United States.

The alleged harm

The concern that drove the litigation was hemorrhagic stroke. Epidemiological studies in the late 1990s linked PPA use — particularly among younger users taking the drug for weight loss — with an increased risk of bleeding into the brain. In November 2000 the FDA issued a public health advisory recommending that consumers not use PPA products and asking, though not requiring, manufacturers to discontinue them; the agency's estimate suggested the drug was associated with hundreds of strokes per year among young adult users. In the wake of the advisory, manufacturers voluntarily withdrew PPA-containing products from the U.S. market, and other countries followed, including Canada and Australia in 2001. The FDA subsequently removed PPA from over-the-counter sale and withdrew its "generally recognized as safe and effective" status in 2005. PPA remains available in some jurisdictions and continues to be used in veterinary medicine, notably for urinary incontinence in dogs.

The litigation

Stroke victims and their families brought products-liability and related claims against the manufacturers and distributors of PPA products in federal and state courts. The federal cases were centralized in the United States District Court for the Western District of Washington as In re Phenylpropanolamine (PPA) Products Liability Litigation, MDL No. 1407 (docket 2:01-md-01407-BJR), before Judge Barbara J. Rothstein.

The central issues in the MDL were causation and warning: whether PPA caused the plaintiffs' hemorrhagic strokes, and whether the makers of PPA products had failed to warn of that risk. Plaintiffs relied on the epidemiological literature and on the FDA's own findings; the defense side contested the strength of the causal association and pointed to the product labeling and to the fact that the FDA had issued an advisory rather than an order when it first acted on the risk.

The Ninth Circuit Court of Appeals issued an opinion in the litigation in 2006 (460 F.3d 1217).

Disposition

The archived record for this MDL does not confirm a final settlement or termination date, and none is stated in this entry. The case is recorded here as documented in the primary sources listed below; the final disposition of the consolidated cases is not established in those sources.

The PPA program is one of the more prominent examples of mass-tort litigation arising from a low-dose, widely used consumer product whose risks were identified through population-level studies rather than through a single dramatic clinical event.